TWSTTwist Bioscience Corp

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Emily M. Leproust

Location

California, USA

Exchange

Nasdaq

Website

https://twistbioscience.com

Summary

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products.

Company Info

CEO

Emily M. Leproust

Location

California, USA

Exchange

Nasdaq

Website

https://twistbioscience.com

Summary

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products.

AI Insights for TWST
6 min read

Quick Summary

Twist Bioscience Corporation is a synthetic biology company that manufactures and sells synthetic DNA-based products using a silicon-chip DNA synthesis platform. The company writes DNA on silicon chips and uses that platform to produce synthetic genes, oligonucleotide pools, antibody discovery tools, sample-preparation products, and emerging DNA data-storage technologies. Its customers include pharmaceutical companies, biotechnology companies, academic laboratories, government research groups, diagnostics developers, and technology partners working on artificial intelligence-enabled biology. Twist is positioned at the intersection of life sciences, drug discovery, genomics, and synthetic biology, which means its products can be used in research, therapeutic development, diagnostics, and industrial biology. The company remains unprofitable based on the provided data, with negative EPS and negative net income, but revenue growth, platform validation, and market enthusiasm have supported a much higher valuation.

Strengths

•

Twist Bioscience’s primary strength is its synthetic DNA manufacturing platform, which uses silicon-chip technology to produce DNA at scale.

•

This platform gives the company a differentiated identity in synthetic biology and supports multiple product categories, including genes, sequencing tools, antibody discovery, and data-storage applications.

•

The company is exposed to attractive growth markets such as genomics, AI-enabled drug discovery, synthetic biology, antibody therapeutics, and possibly long-term DNA data storage.

•

Recent partnerships and platform involvement with major players such as Eli Lilly and Amazon-related efforts provide external validation and increase investor confidence in the company’s technological relevance.

•

Twist also has strong market sentiment based on the provided sentiment rating and has benefited from a powerful stock rally that raises visibility with investors and potential partners.

Key Risks

•

Twist faces substantial valuation risk because the market capitalization and revenue multiple imply very high expectations for future growth.

•

If the company fails to move toward profitability or if operating losses persist longer than expected, investors may reassess the stock’s premium valuation.

•

Competitive risk is meaningful because established companies such as IDT, Thermo Fisher, Genscript, and other life-science tool providers can compete on price, scale, service, and distribution.

•

Technology risk is also important because synthetic DNA manufacturing, antibody discovery, and DNA storage are complex fields where performance, accuracy, cost, and scalability matter.

What to Watch

The most recent quarter showed Twist Bioscience as a high-growth, high-expectation company with total revenue of 118.376 million and gross profit of 62.454 million.
Despite this revenue base, the company reported negative operating income of 36.28 million and net income of negative 35.051 million, reinforcing that profitability remains a central issue.
A major event highlighted in recent news was Twist’s announcement that it will join Eli Lilly’s AI-powered TuneLab drug discovery platform.
Twist is expected to contribute antibody characterization data and its AbLab prediction model, which could help researchers screen antibody candidates more efficiently.
Another important development was the DNA data-storage asset transaction, in which Atlas Data Storage raised capital and acquired DNA storage assets from Twist Bioscience.
The quarter also featured notable investor activity, as Cathie Wood’s Ark ETFs sold 11.2 million dollars of Twist shares in June while still reportedly maintaining large stakes, suggesting profit-taking or portfolio reallocation after a major stock rally.

Price Drivers

•

Twist Bioscience’s stock price is being driven by a mix of rapid revenue growth expectations, excitement around synthetic biology, and investor enthusiasm for AI-enabled drug discovery.

•

Recent news indicates that the stock has risen more than fivefold in 2026, which suggests momentum and valuation expansion are major near-term factors.

•

Partnerships and platform validation, especially involvement with Eli Lilly’s AI-powered TuneLab and the Amazon Bio Discovery-related news, appear to be important catalysts because they suggest that large technology and pharmaceutical partners see value in Twist’s data and tools.

•

However, the company remains unprofitable, with negative EPS, negative net income, and negative operating income, so earnings quality and the path to profitability are important risks for the stock.

•

Valuation is also a key driver because the provided EV-to-revenue ratio above 21 and price-to-book ratio above 21 indicate that investors are already pricing in substantial future growth.

•

Broader biotech sentiment, interest rates, risk appetite, AI enthusiasm, and genomics-sector spending trends can all amplify price moves because the stock has a high beta of 2.192.

Recent News

•

Recent news has been highly favorable toward Twist Bioscience but also emphasizes risk after a large share-price increase.

•

One report said Twist’s stock was up more than fivefold in 2026 due to rising synthetic DNA sales, while also noting that analysts see possible pullbacks and suggest waiting for better entry points.

•

Cathie Wood’s Ark ETFs reportedly sold 11.2 million dollars of Twist shares in June, but still held large stakes, which was interpreted as possible profit-taking or reallocation rather than a full loss of confidence.

•

Twist also gained attention after announcing it would join Eli Lilly’s AI-powered TuneLab drug discovery platform and provide antibody characterization data, including its AbLab prediction model.

•

The stock reportedly jumped over 31 percent after that announcement, showing how strongly investors are reacting to AI and pharma partnership news.

•

Another notable development was Atlas Data Storage raising 155 million dollars in seed funding and acquiring DNA storage assets from Twist, which highlights both the promise and strategic reshaping of Twist’s DNA data-storage involvement.

Market Trends

•

Twist Bioscience is affected by several powerful market trends, including growth in synthetic biology, genomics, antibody therapeutics, AI-enabled drug discovery, and long-term data storage innovation.

•

Cheaper and faster genome sequencing is increasing the amount of biological data available and supporting demand for sample-preparation tools and custom DNA products.

•

Pharmaceutical companies are increasingly exploring AI partnerships to accelerate drug discovery, which can benefit companies like Twist that provide biological datasets, antibody libraries, and screening tools.

•

The DNA data-storage market is projected by Verified Market Research to grow rapidly from 126.76 million dollars in 2024 to 6.24 billion dollars by 2032, although cost, speed, and standards remain major barriers.

•

Biotech stocks can experience large swings based on clinical data, funding conditions, interest rates, and investor appetite for long-duration growth assets.

•

Twist benefits from these trends when investors favor innovation and platform companies, but it is also exposed to downside if enthusiasm for biotech, genomics, or AI-themed stocks fades.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on TWST

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show